Skip to main content

Economics

Rheum Scholarship (8.21.2026)

Dr. Cush reviews the news and journal articles from this past week on RheumNow.com; talking about lumbar belts, scholarships and misdiagnosis.

Read Article

Joint Pain Prevalence is not Declining

A current report from the national NHIS survey shows that over half of US adults diagnosed with arthritis reported moderate to severe joint pain.

Read Article

JAMA: Review of Shoulder Pain

Shoulder pain affects 16% of adults annually and is the third most common musculoskeletal presentation in primary care. This new review reframes the diagnostic and therapeutic approach, moving away from pathoanatomic labels (rotator cuff tendinopathy, impingement, bursitis) toward the umbrella

Read Article

Can Effective Psoriasis Therapy Prevent Psoriatic Arthritis?

A review article assesses and integrates mechanistic, imaging, and clinical evidence to examine whether effective treatment of psoriasis may modify the future risk of psoriatic arthritis (PsA).

Read Article

Doubting RS3PE (8.14.2026)

Dr. Jack Cush reviews the news and journal articles this week where RheumNow featured info on cancer, deadly viruses, AI rules, poetry and good moons rising.

Read Article
2026 PGY1 match for non–US citizen international medical graduates (IMGs) has reached a 5-year low; yet US health care relies heavily on non–US-born MDs. In US, there are 6300 Rheumatologists - 46.9% US born USMG; 5.4% US born IMG; 11.2% non-US born USMG; 36.5% non-US born IMG https://t.co/cwx5ugBaVE
Dr. John Cush @RheumNow( View Tweet )
Wealth and Where you Live Influences Outcomes Patients from wealthier European countries tend to start treatment with biologics earlier but also stop or switch treatment earlier. They also experience lower disease activity at treatment start than patients in middle- and https://t.co/MyzWRx580R
Dr. John Cush @RheumNow( View Tweet )

ZEUS Trial: IL-6 Inhibition Fails to Cut Cardiovascular Events

The phase 3 ZEUS trial (published in JAMA Dec. 2025)  tested the IL-6 ligand inhibitor ziltivekimab in over 6,000 patients with atherosclerotic cardiovascular disease, chronic kidney disease, and elevated hsCRP—a population enriched for an inflammatory driver of risk.

Read Article

2026 BSR Pain Guideline: What Rheumatologists Need to Know

The British Society for Rheumatology has issued its first guideline dedicated solely to pain in inflammatory arthritis (IA)—covering RA, PsA, axial SpA and JIA.

Read Article

Updated Guidance for Artificial Intelligence Use in Medical Publications

JAMA has updated its guidance for the acceptable use of artificial intelligence (AI) in authoring a medical publication. Despite growing AI use, very low rates of disclosure of AI use have been reported. This update provides specific information about what is permitted and not permitted, and

Read Article
NP Salaries: in 7 specialties, NPs now avg >$150,000/yr, with the avg annual salary surpassing $137,000 in 2026 according toBureau of Labor Statistics. https://t.co/LlGFxkvEj5 https://t.co/h5bKsrnm4k
Dr. John Cush @RheumNow( View Tweet )

Wealth and Where you Live Influences Outcomes

EurekAlert!

Patients from wealthier European countries tend to start treatment with biologics earlier but also stop or switch treatment earlier. They also experience lower disease activity at treatment start than patients in middle- and low-income countries.

Read Article
JAMA Review of Hip Fracture The July 16th edition of JAMA reviews the highly prevalent problem of hip fractures - a major global health burden: 14.2 million occur worldwide annually (280,000 in the US), with global incidence higher in women (833.9/100,000) than men https://t.co/KBUovkYPB1
Dr. John Cush @RheumNow( View Tweet )

Mentshlichkeit* (8.7.2026)

Dr. Jack Cush reviews the news and recent journal reports on RheumNow.com.

Read Article

Top 20 Best Rheumatology Hospitals

U.S. News & World Report has published its Best Hospitals for 2026-2027, listing the best among many specialties, including rheumatology.  Each year U.S. News Best Hospitals ranked hospitals in the U.S. in 14 adult specialties and for the 9th year in a row, Johns Hopkins Hospital in

Read Article

Methotrexate Safety Tips (7.31.2026)

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.

Read Article

New Avacopan Analysis Sent to FDA

MedPage Today

After data manipulation allegations, the FDA has been calling for the vasculitis drug to be pulled from the market since January.

Amgen has submitted a third-party review of avacopan's (Tavneos) pivotal trial data and other analyses to the FDA in a bid to keep the embattled drug for

Read Article

$2 Million in Research Grants for Juvenile Arthritis

July is Juvenile Arthritis Awareness Month, and while many people think of arthritis as a disease of aging, nearly 300,000 children in the U.S. are living with a rheumatic disease.

Equally important is that 2026 marks a 50 year anniversary for Pediatric

Read Article

Chikungunya Club Meeting (7.24.2026)

Dr. Jack Cush reviews the news, journal reports from the past week on RheumNow.com.

Read Article

Swimming Reduces Disability from Low Back Pain

EurekAlert!

Swimming is commonly recommended for patients with chronic low back pain. Yet, there is little trial data investigating swimming. An Australian study has shown for the first time that a program of swimming can be clinically effective in reducing disability from chronic low back pain

Read Article

ACP Position Paper on Dietary Supplements

More than half of U.S. adults use dietary supplements, yet only a quarter use supplements recommended by a healthcare professional, and current law lets supplements reach the market with no premarket safety evaluation, unlike drugs or food additives. The paper notes that under DSHEA, dietary

Read Article

Guidelines to Spot Cancer in High Risk Dermatomyositis

MedPage Today

International guidelines can help identify dermatomyositis patients with a particularly high risk for cancer, according to a retrospective single-center U.S. study.

Read Article

Gout Cavalcade (7.10.2026)

Dr. Jack Cush reviews the news, journal articles and regulatory decisions from the past week. July is Gout: More than Flares month.

Read Article

Do we need Better Strategies to Prevent Osteoporotic Fractures?

In a recent JAMA Viewpoints article, Dr. Susan Ott addresses several controversies in preventing osteoporosis (OP) related fractures.

Read Article
The global Chronic Refractory Gout Market is projected to grow from ~$2.94 billion USD in 2022 to nearly $10.07 billion USD by 2036, reflecting introduction of innovative therapies. Chronic Refractory Gout in the 7Major Markets exceeded 400,000 pts in 2025 (>200K in USA) https://t.co/MSzBNTXTPj
Dr. John Cush @RheumNow( View Tweet )
×